STING1 and breast cancer: Y. Kitai et al. treated breast cancer cells with an inhibitor of topoisomerase I before they collected and extracted cancer-derived EVs which could contain a larger volume of DNA, and then DCs were activated to elicit antitumor immunity by the TEVs via the cGAS-STING pathway [79].